← Back to Search

CT Perfusion Imaging for Subarachnoid Hemorrhage (CT-PIPS Trial)

N/A
Waitlist Available
Led By Gwynedd E Pickett, MD
Research Sponsored by Nova Scotia Health Authority
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights

CT-PIPS Trial Summary

This trialwill test if CT scans can predict which SAH patients are at risk of stroke from vasospasm, helping to improve their outcomes.

Who is the study for?
This trial is for individuals aged 18-75 who have had a brain hemorrhage due to a ruptured aneurysm and can consent to participate. They must be able to attend follow-up visits and not be in another study, pregnant, breastfeeding, or expected to pass away within 24 hours.Check my eligibility
What is being tested?
The trial tests if CT perfusion scans can predict vasospasm—a dangerous narrowing of blood vessels in the brain after hemorrhage—by performing scans when patients are admitted and again on day six.See study design
What are the potential side effects?
CT perfusion involves exposure to radiation similar to that of regular CT scans. Potential side effects include allergic reactions to contrast material used during the scan, such as itching or rash.

CT-PIPS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
CBF Admit
CBF day 6
CBV Admit
+5 more
Secondary outcome measures
Radiation Dose
Other outcome measures
Delayed Cerebral Ischemia

CT-PIPS Trial Design

1Treatment groups
Experimental Treatment
Group I: CT PerfusionExperimental Treatment1 Intervention
All patients enrolled in the study
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CT Perfusion
2021
N/A
~300

Find a Location

Who is running the clinical trial?

Nova Scotia Health AuthorityLead Sponsor
258 Previous Clinical Trials
83,813 Total Patients Enrolled
Gwynedd PickettLead Sponsor
Gwynedd E Pickett, MDPrincipal InvestigatorCapital District Health Authority, Halifax, Canada

Media Library

CT Perfusion Clinical Trial Eligibility Overview. Trial Name: NCT02056769 — N/A
Subarachnoid Hemorrhage Research Study Groups: CT Perfusion
Subarachnoid Hemorrhage Clinical Trial 2023: CT Perfusion Highlights & Side Effects. Trial Name: NCT02056769 — N/A
CT Perfusion 2023 Treatment Timeline for Medical Study. Trial Name: NCT02056769 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this clinical trial include participants over 20 years old?

"To be eligible for this trial, participants must fall between the age of 18 and 75. Moreover, there are 94 trials available to minors and 668 specifically catering to those over 65."

Answered by AI

Do I fulfill the requirements necessary to join this medical research?

"Qualified applicants to this clinical trial must have a diagnosis of subarachnoid hemorrhage and be between the ages of 18 and 75. The total number of patients that are allowed to take part in the study is capped at 41."

Answered by AI

Are there available opportunities for individuals to join this medical trial?

"According to clinicaltrials.gov, this medical trial is not currently recruiting patients; the study was initially published on April 1st 2014 and last modified on February 6th 2023. Despite no longer being open for enrollment, there are still 774 other trials actively seeking participants."

Answered by AI
~4 spots leftby Apr 2025